IPSEN (OTCMKTS:IPSEY) Given Average Rating of “Hold” by Brokerages

IPSEN (OTCMKTS:IPSEY) has been assigned an average recommendation of “Hold” from the six brokerages that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and two have assigned a buy recommendation to the company.

IPSEY has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Zacks Research raised shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Jefferies Financial Group downgraded shares of IPSEN to an “underperform” rating in a research note on Sunday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th.

IPSEN Price Performance

Shares of IPSEY traded up $2.59 during mid-day trading on Friday, reaching $47.68. 276 shares of the company were exchanged, compared to its average volume of 781. IPSEN has a 52 week low of $30.05 and a 52 week high of $51.10. The business has a 50 day simple moving average of $45.87 and a two-hundred day simple moving average of $45.56.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).